Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Jenny Devenport"'
Autor:
Jeffrey R. Curtis, Jan Michael Nebesky, Elodie de Bock, Christine de la Loge, Benoit Arnould, Robert Davey, Jenny Devenport, Attila Pethö-Schramm
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 5, Iss 1, Pp 1-12 (2021)
Abstract Objective Despite the development of new biologic therapies, methotrexate (MTX) remains the preferred initial disease-modifying anti-rheumatic drug to treat rheumatoid arthritis (RA). Adherence to disease-modifying anti-rheumatic drugs is su
Externí odkaz:
https://doaj.org/article/481b0d94b6924eeeaa605a60e5432c79
Autor:
Xavier M Teitsma, Jenny Devenport, Johannes W G Jacobs, Attila Pethö-Schramm, Michelle E A Borm, Petra Budde, Johannes W J Bijlsma, Floris P J G Lafeber
Publikováno v:
PLoS ONE, Vol 15, Iss 12, p e0241189 (2020)
BackgroundWe sought to identify immunoglobin G autoantibodies predictive of early treatment response to methotrexate, the recommended first-line therapy for patients with newly diagnosed rheumatoid arthritis, and to the interleukin-6 receptor inhibit
Externí odkaz:
https://doaj.org/article/557adbab940945f3954d2ed95caccb31
Autor:
Attila Pethö-Schramm, Jan Michael Nebesky, Jenny Devenport, Benoit Arnould, Elodie de Bock, Jeffrey R. Curtis, Christine de la Loge, Robert Davey
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 5, Iss 1, Pp 1-12 (2021)
Journal of Patient-Reported Outcomes
Journal of Patient-Reported Outcomes
Objective Despite the development of new biologic therapies, methotrexate (MTX) remains the preferred initial disease-modifying anti-rheumatic drug to treat rheumatoid arthritis (RA). Adherence to disease-modifying anti-rheumatic drugs is suspected t
Autor:
Daniel Aletaha, Andrea Rubbert-Roth, Michael D Edwardes, Paris Sidiropoulos, Jenny Devenport, Johannes W G Jacobs, Yves Luder
Publikováno v:
Rheumatology (Oxford, England)
Objective To determine the extent to which disease duration, alone or in combination with other baseline clinical and non-clinical factors, explains variations in outcome of tocilizumab initiated in biologic-naïve patients with established RA. Metho
Autor:
Yves Luder, Mary Safy-Khan, Xavier M Teitsma, Johannes W. J. Bijlsma, Maria J.H. de Hair, Attila Pethoe-Schramm, Johannes W G Jacobs, Paco M J Welsing, Michael D Edwardes, Jacob M van Laar, Jenny Devenport
Publikováno v:
Annals of the Rheumatic Diseases. 79:460-463
BackgroundIn rheumatoid arthritis (RA) trials, inclusion of patients on background treatment with glucocorticoids (GCs) might impact efficacy and safety outcomes.ObjectivesTo determine if inclusion of patients on background GC use influenced efficacy
Autor:
Renata Langfort, Keith M. Kerr, Jiří Votruba, Kerstin Trunzer, Hans-Ulrich Schildhaus, Christine Boyiddle, Federico Cappuzzo, Jenny Devenport, Ángel Concha‐López, Isabel Esteban-Rodríguez, Lukas Bubendorf, Janine Feng, Esther Conde, S. Morris
Publikováno v:
Cancer Cytopathology
Background The diagnosis of advanced lung cancer is made with minimally invasive procedures. This often results in the availability of cytological material only for subtype determination and companion diagnostic testing, with the latter being technic
Autor:
Floris P J G Lafeber, Petra Budde, Johannes W. J. Bijlsma, Xavier M Teitsma, Johannes W G Jacobs, Attila Pethö-Schramm, Jenny Devenport, Michelle E A Borm
Publikováno v:
PLoS ONE, Vol 15, Iss 12, p e0241189 (2020)
PLoS ONE
PLoS ONE
Background We sought to identify immunoglobin G autoantibodies predictive of early treatment response to methotrexate, the recommended first-line therapy for patients with newly diagnosed rheumatoid arthritis, and to the interleukin-6 receptor inhibi
Autor:
Michael T. Nurmohamed, Jean Sibilia, José Andrés Román Ivorra, Andrew J. K. Östör, Yves Luder, Karel Pavelka, Jenny Devenport, José María Álvaro-Gracia, Paris Sidiropoulos, Vivian P. Bykerk
Publikováno v:
Bykerk, V P, Östör, A J K, Alvaro-Gracia, J, Pavelka, K, Román Ivorra, J A, Nurmohamed, M T, Luder, Y, Sidiropoulos, P N M, Devenport, J & Sibilia, J 2019, ' Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors : an open-label study close to clinical practice ', Clinical Rheumatology, vol. 38, no. 9, pp. 2411-2421 . https://doi.org/10.1007/s10067-019-04535-z
Clinical Rheumatology, 38(9), 2411-2421. Springer London
Clinical Rheumatology, 38(9), 2411-2421. Springer London
OBJECTIVE: To assess the long-term safety, tolerability, and effectiveness of tocilizumab (TCZ) as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in clinical practice in patients with modera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2be02bbc05055baacba31a58c7b83c55
https://research.vumc.nl/en/publications/ae691602-07fc-4a1b-a4e2-b35a473500f7
https://research.vumc.nl/en/publications/ae691602-07fc-4a1b-a4e2-b35a473500f7
Autor:
Jenny Devenport, Markus R. John, Frank Buttgereit, J. Michael Nebesky, Gerd R Burmester, Marc Y. Donath
Publikováno v:
Oral Presentations.
Background Glucocorticoids (GCs) directly impact bone metabolism via increased bone resorption and inhibited bone formation1; hence, systemic fracture risk increases with daily and cumulative GC doses.2 However, many patients with established rheumat
Autor:
Andrea Rubbert-Roth, Michael D Edwardes, Jenny Devenport, Daniel Aletaha, Johannes W G Jacobs, Yves Luder, Paris Sidiropoulos
Publikováno v:
Abstracts Accepted for Publication.
Background Tocilizumab (TCZ) efficacy and safety in rheumatoid arthritis (RA) have been well established by numerous phase 3 and 4 studies and observational studies. Objectives To explore the extent to which disease duration, inflammation, disease bu